Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,298 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Treatment Response Clear all

Conditions: Diabetic Retinopathy
Interventions: BI 765128, Sham comparator; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more

Conditions: Psoriatic Arthritis
Interventions: adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Major Depressive Disorder With Anxious Distress
Interventions: JNJ-61393215, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Garden Grove, California • Alpharetta, Georgia • Atlanta, Georgia + 6 more

Conditions: Cholestasis
Interventions: Placebo, GSK2330672; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • Miami, Florida + 6 more

Conditions: Head and Neck Cancer
Interventions: Patient-specific dosimetry; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Placebo, tocilizumab [RoActemra/Actemra]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 76
States / cities: Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more

Conditions: Nasopharyngeal Cancer
Interventions: PET/CT scans; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2012
U.S. locations: 93
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: HIV Infections
Interventions: Vicriviroc; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more

Conditions: Parkinson's Disease
Interventions: KW-6002 (istradefylline); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn Disease
Interventions: Sargramostim (Leukine), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • New Orleans, Louisiana + 4 more

Conditions: Diabetes
Interventions: Thymosin Beta 4 (Tβ4), Placebo; Drug · Other
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Inglewood, California • Los Angeles, California • Orlando, Florida + 2 more

Conditions: Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions: MQX-503; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Timeline: 2006
U.S. locations: 1
States / cities: Renton, Washington

Conditions: Breast Cancer Stage, Insulin Resistance, Racial Bias
Interventions: Metformin Extended Release Oral Tablet; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 39
States / cities: Vestavia Hills, Alabama • Tucson, Arizona • Carlisle, Arkansas + 32 more

Conditions: HIV Infections
Interventions: Therapeutic vaccinations from A5058s; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 14
States / cities: Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more

Conditions: Physiological Measurements of Response and Reaction Times
Interventions: Chiropractic Manipulative Therapy, Wait-list; Other
Lead sponsor: RAND; Other
Eligibility: 20 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Fort Campbell North, Kentucky

Conditions: Pneumonia, Necrotizing Soft Tissue Infection, Intraabdominal Infections, Infection Joint
Interventions: Blue Light; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obsessive-Compulsive Disorder
Interventions: Activa PC+S DBS implant for OCD, One Month Blinded Discontinuation Period; Device · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas

Conditions: Central Line-Associated Bloodstream Infection
Interventions: ethanol, heparin-saline placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Months to 25 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Infective Endocarditis
Interventions: daptomycin, daptomycin and gentamicin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Tabalumab Auto-Injector, Tabalumab Prefilled Syringe; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 14
States / cities: Glendale, Arizona • Lewes, Delaware • DeBary, Florida + 11 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Summit RC+S System, One Month Blinded Discontinuation Period:; Device · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas

Search by objective public record fields.

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

A Study of JNJ-61393215 in the Treatment of Depression

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Iodine I 131 in Treating Patients With Thyroid Cancer

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

Assessment of Chiropractic Treatment Using Reaction and Response Times in Members of the Special Operation Forces (ACT2)

The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

Development of Adaptive Deep Brain Stimulation for OCD (Phase 1a)

Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)

Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)

Development of Adaptive Deep Brain Stimulation for OCD